Preclinical Evaluation of Antiarrhythmic Drugs Against Atrial Fibrillation in Experimental Animal Models

CVD are the leading cause of death and disability worldwide and arrhythmias, in particular AF, are one of the main causes of death and disability from CVD. In this regard, the main purpose of the work is to conduct preclinical studies on the analysis of promising anti-ventricular fibrillation, as well as anti-atrial fibrillation among known drugs with antiarrhythmic activity, widely used in medical practice. The studies used white mice with a body weight of 18-22 g and white woolless rats with a body weight of 180-250 g. The experiments studied the antiarrhythmic activity of drugs with antiarrhythmic activity of allapinine in doses from 0.05 to 1.5 mg/kg, propafenone from 3 to 10 mg/kg and Amiodarone in doses from 45 to 60 mg/kg administered orally to experimental animals. Rhythm disturbances of peripheral origin were caused by the administration of 15 mg/kg of aconitine and barium chloride, 250 mg/kg of calcium chloride, 0.22 mcg/kg of adrenal hydrochloride and AF by injecting 200 mcg/kg of aconitine into the tail vein of experimental animals. In the conducted studies, allapinine, propafenone and amiodarone also primarily eliminated ventricular rhythm disturbances and then restored the rhythm of the atria. Although the instructions for the use of these drugs in clinical practice also mention ventricular rhythm disorders, in practice we see that these drugs mainly eliminate ventricular rhythm disorders. The quest for methods to broaden the scope of the use of medications that prevent AF is still relevant in medical practice, even though large-scale, important studies of antiarrhythmic pharmaceuticals are now being conducted worldwide.

Hali tarjima qilinmagan